• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Alvotech (ALVO) Is Up 11.7% After Lotus Biosimilar Licensing Deal and 2026 Guidance Update – Has The Bull Case Changed?

    Simply Wall St·08/30/2026 09:24:38
    Listen to the news
    • In August 2026, Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical for biosimilar candidates AVT34 and AVT87 in the United States and eight Asian markets, alongside full-year 2026 revenue guidance of US$650–US$700 million and a half-year net loss of US$65.79 million.
    • The Lotus deal, with potential value of up to about US$150 million in upfront and milestone payments plus ongoing supply revenues, underlines how Alvotech is using partnerships to broaden market access while keeping control over development, approvals and manufacturing.
    • We’ll now examine how this Lotus licensing agreement, particularly its semi-exclusive U.S. structure and Asian reach, reshapes Alvotech’s investment narrative.

    Outshine the giants: these 18 early-stage AI stocks could fund your retirement.

    Alvotech Investment Narrative Recap

    To own Alvotech today, you need to believe its focused biosimilar model can turn a volatile, partner‑driven revenue base into sustainable, higher‑quality cash flows. The Lotus agreement fits that story by widening oncology and hematology exposure without adding manufacturing risk, but it does not change the key near term catalyst, which is still timely FDA and EMA decisions on late stage assets, nor the biggest immediate risk around approval driven, “lumpy” milestone revenues.

    Among the recent announcements, the August 2026 full year revenue guidance of US$650–US$700 million is most relevant here. It frames the scale against which any Lotus related milestones and supply income will be judged, and highlights how much of Alvotech’s near term trajectory still hinges on regulatory outcomes for AVT05, AVT16 and other pipeline biosimilars, rather than on a single new licensing deal.

    Yet this focus on approvals and “lumpy” milestones hides an important risk investors should be aware of around...

    Read the full narrative on Alvotech (it's free!)

    Alvotech's narrative projects $1.0 billion revenue and $242.3 million earnings by 2029.

    Uncover how Alvotech's forecasts yield a $5.75 fair value, a 16% upside to its current price.

    Exploring Other Perspectives

    ALVO 1-Year Stock Price Chart
    ALVO 1-Year Stock Price Chart

    Some of the most optimistic analysts already expected Alvotech to reach about US$1.2 billion in revenue and US$360.7 million in earnings by 2029, and the Lotus deal could either support or challenge those aggressive assumptions depending on how it interacts with the company’s tight pipeline focus and partnership dependence.

    Explore 5 other fair value estimates on Alvotech - why the stock might be worth 19% less than the current price!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Ready For A Different Approach?

    Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.